Edition:
India

Elanco Animal Health Inc (ELAN.N)

ELAN.N on New York Stock Exchange

33.68USD
15 Jul 2019
Change (% chg)

$0.37 (+1.11%)
Prev Close
$33.31
Open
$33.33
Day's High
$33.83
Day's Low
$33.07
Volume
946,050
Avg. Vol
1,826,559
52-wk High
$36.50
52-wk Low
$28.50

Latest Key Developments (Source: Significant Developments)

Elanco Announces Research And Development Collaboration With AgBiome For Swine Nutritional Health Innovation
Thursday, 27 Jun 2019 

June 27 (Reuters) - Elanco Animal Health Inc ::ELANCO ANNOUNCES RESEARCH AND DEVELOPMENT COLLABORATION WITH AGBIOME FOR SWINE NUTRITIONAL HEALTH INNOVATION.ELANCO ANIMAL HEALTH INC - TERMS OF DEAL WERE NOT DISCLOSED..ELANCO ANIMAL HEALTH - GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION WITH AGBIOME TO DEVELOP NUTRITIONAL HEALTH PRODUCTS FOR SWINE.  Full Article

Elanco Animal Health Q1 Adjusted Earnings Per Share $0.25
Thursday, 9 May 2019 

Elanco Animal Health Inc ::ELANCO ANIMAL HEALTH REPORTS FIRST QUARTER RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.25.Q1 EARNINGS PER SHARE $0.09.Q1 REVENUE $731.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $743.5 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.23 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $3.08 BILLION TO $3.14 BILLION.SEES FY 2019 EARNINGS PER SHARE $0.36 TO $0.48.EXPECTED 2019 REVENUE UPDATED TO BE BETWEEN $3.08 BILLION AND $3.14 BILLION DUE TO CHANGES IN FOREIGN EXCHANGE RATE ASSUMPTIONS.FY2019 EARNINGS PER SHARE VIEW $1.08, REVENUE VIEW $3.13 BILLION -- REFINITIV IBES DATA.EXPECTED 2019 CONSTANT CURRENCY REVENUE GROWTH AT 4 TO 6 PERCENT REMAINS UNCHANGED.SEES 2019 EARNINGS PER SHARE $1.02 TO $1.12 ON AN ADJUSTED BASIS.FY2019 EARNINGS PER SHARE VIEW $1.08, REVENUE VIEW $3.13 BILLION -- REFINITIV IBES DATA.  Full Article

Eli Lilly And Co Qtrly Non-GAAP EPS $1.33
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Eli Lilly And Co ::LILLY REPORTS SOLID FIRST-QUARTER 2019 FINANCIAL RESULTS, UPDATES 2019 GUIDANCE TO REFLECT DISPOSITION OF ELANCO ANIMAL HEALTH.SEES FY 2019 EARNINGS PER SHARE $8.57 TO $8.67.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $5.60 TO $5.70.QTRLY EPS REPORTED $4.31.IN Q1 OF 2019, WORLDWIDE REVENUE WAS $5.092 BILLION, AN INCREASE OF 3 PERCENT COMPARED WITH Q1 OF 2018.2019 EPS GUIDANCE UPDATED TO BE IN RANGE OF $8.57 TO $8.67 ON A REPORTED BASIS AND $5.60 TO $5.70 ON A NON-GAAP BASIS.QTRLY EPS - NON-GAAP $1.33.FIRST-QUARTER 2019 WORLDWIDE TRULICITY REVENUE WAS $879.7 MILLION, AN INCREASE OF 30 PERCENT COMPARED WITH Q1 OF 2018.FIRST-QUARTER 2019 EPS ON A REPORTED BASIS INCLUDES GAIN ON SALE ASSOCIATED WITH DISPOSITION OF ELANCO ANIMAL HEALTH.FOR Q1 OF 2019, WORLDWIDE HUMALOG REVENUE DECREASED 8 PERCENT COMPARED WITH Q1 OF 2018, TO $730.8 MILLION.FOR Q1 OF 2019, WORLDWIDE TALTZ REVENUE WAS $252.5 MILLION, AN INCREASE OF 72 PERCENT COMPARED WITH Q1 OF 2018.IN Q1 OF 2019, COMPANY RECOGNIZED ASSET IMPAIRMENT, RESTRUCTURING, AND OTHER SPECIAL CHARGES OF $423.9 MILLION.COMPANY ANTICIPATES 2019 REVENUE BETWEEN $22.0 BILLION AND $22.5 BILLION.2019 REVENUE GROWTH IS EXPECTED TO BE DRIVEN BY VOLUME FROM "KEY GROWTH" PRODUCTS INCLUDING TRULICITY, TALTZ, BASAGLAR, JARDIANCE.CHARGES IN QUARTER WERE PRIMARILY ASSOCIATED WITH ACCELERATED VESTING OF LOXO ONCOLOGY EMPLOYEE EQUITY AWARDS.Q1 EARNINGS PER SHARE VIEW $1.31, REVENUE VIEW $5.13 BILLION -- REFINITIV IBES DATA.  Full Article

Eli Lilly And Co posts Qtrly Non-GAAP EPS of $1.33
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Eli Lilly And Co ::LILLY REPORTS SOLID FIRST-QUARTER 2019 FINANCIAL RESULTS, UPDATES 2019 GUIDANCE TO REFLECT DISPOSITION OF ELANCO ANIMAL HEALTH.SEES FY 2019 EARNINGS PER SHARE $8.57 TO $8.67.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $5.60 TO $5.70.QTRLY EPS REPORTED $4.31.IN Q1 OF 2019, WORLDWIDE REVENUE WAS $5.092 BILLION, AN INCREASE OF 3 PERCENT COMPARED WITH Q1 OF 2018.2019 EPS GUIDANCE UPDATED TO BE IN RANGE OF $8.57 TO $8.67 ON A REPORTED BASIS AND $5.60 TO $5.70 ON A NON-GAAP BASIS.QTRLY EPS - NON-GAAP $1.33.FIRST-QUARTER 2019 WORLDWIDE TRULICITY REVENUE WAS $879.7 MILLION, AN INCREASE OF 30 PERCENT COMPARED WITH Q1 OF 2018.FIRST-QUARTER 2019 EPS ON A REPORTED BASIS INCLUDES GAIN ON SALE ASSOCIATED WITH DISPOSITION OF ELANCO ANIMAL HEALTH.FOR Q1 OF 2019, WORLDWIDE HUMALOG REVENUE DECREASED 8 PERCENT COMPARED WITH Q1 OF 2018, TO $730.8 MILLION.FOR Q1 OF 2019, WORLDWIDE TALTZ REVENUE WAS $252.5 MILLION, AN INCREASE OF 72 PERCENT COMPARED WITH Q1 OF 2018.IN Q1 OF 2019, COMPANY RECOGNIZED ASSET IMPAIRMENT, RESTRUCTURING, AND OTHER SPECIAL CHARGES OF $423.9 MILLION.COMPANY ANTICIPATES 2019 REVENUE BETWEEN $22.0 BILLION AND $22.5 BILLION.2019 REVENUE GROWTH IS EXPECTED TO BE DRIVEN BY VOLUME FROM "KEY GROWTH" PRODUCTS INCLUDING TRULICITY, TALTZ, BASAGLAR, JARDIANCE.CHARGES IN QUARTER WERE PRIMARILY ASSOCIATED WITH ACCELERATED VESTING OF LOXO ONCOLOGY EMPLOYEE EQUITY AWARDS.Q1 EARNINGS PER SHARE VIEW $1.31, REVENUE VIEW $5.13 BILLION -- REFINITIV IBES DATA.  Full Article

Lilly Announces Preliminary Results Of Elanco Exchange Offer
Monday, 11 Mar 2019 

March 11 (Reuters) - Elanco Animal Health Inc ::LILLY ANNOUNCES PRELIMINARY RESULTS OF ELANCO EXCHANGE OFFER.ELI LILLY AND CO - ESTIMATED THAT ABOUT 13.2 PERCENT OF TENDERED SHARES OF LILLY COMMON STOCK WILL BE EXCHANGED.ELI LILLY AND CO - LILLY EXPECTS TO ANNOUNCE FINAL PRORATION FACTOR ON MARCH 13, 2019.ELI LILLY AND CO - LILLY WILL RECOGNIZE ONLY PARTIAL-YEAR BENEFIT FOR REDUCTION IN COMMON STOCK FOR GAAP WEIGHTED-AVERAGE DILUTED SHARES OUTSTANDING.  Full Article

Lilly Will Initiate Divestiture Of Its Remaining Interest In Elanco Animal Health
Friday, 8 Feb 2019 

Feb 8 (Reuters) - Elanco Animal Health Inc ::LILLY WILL INITIATE DIVESTITURE OF ITS REMAINING INTEREST IN ELANCO ANIMAL HEALTH.LILLY- TO PERMIT EXCHANGE OF CO'S SHARES FOR ELANCO SHARES AT 7 PERCENT DISCOUNT, SUBJECT TO UPPER LIMIT 4.5262 SHARES OF ELANCO STOCK/SHARE OF CO'S STOCK.ELI LILLY - IN EXCHANGE OFFER, CO SHAREHOLDERS CAN EXCHANGE THEIR SHARES OF CO STOCK FOR SHARES OF ELANCO STOCK OWNED BY LILLY, SUBJECT TO PRORATION.LILLY - IF UPPER LIMIT NOT IN EFFECT, FOR EACH $100 OF SHARES OF CO IN EXCHANGE OFFER, TENDERING SHAREHOLDERS TO GET ABOUT $107.53 OF ELANCO STOCK.ELI LILLY AND CO - TO PERMIT EXCHANGE OFFER TO OCCUR, LILLY HAS RECEIVED A WAIVER OF 180-DAY LOCK-UP FROM JOINT LEAD BOOK-RUNNING MANAGERS OF IPO.ELI LILLY - EXCHANGE OFFER EXPECTED TO BE TAX-FREE FOR PARTICIPATING HOLDERS IN U.S., EXCEPT WITH RESPECT TO CASH RECEIVED IN LIEU OF FRACTIONAL SHARES.LILLY - LARGEST POSSIBLE NUMBER OF SHARES OF CO'S COMMON STOCK THAT WILL BE ACCEPTED IN EXCHANGE OFFER IS 293.29 MILLION DIVIDED BY FINAL EXCHANGE RATIO.LILLY - IF EXCHANGE OFFER IS UNDERSUBSCRIBED, LILLY WOULD EXCHANGE LESS THAN 293.29 MILLION SHARES OF ELANCO COMMON STOCK.ELI LILLY AND CO - IF EXCHANGE OFFER IS UNDERSUBSCRIBED LILLY WOULD CONTINUE TO OWN AN INTEREST IN ELANCO.LILLY - IF CO CONTINUES TO OWN INTEREST IN ELANCO AFTER OFFER, INTENDS TO CONDUCT ADDITIONAL EXCHANGE OFFERS OR PAY SPECIAL DIVIDEND OF ELANCO SHARES.  Full Article

Lilly Lowers 2019 EPS Guidance To Reflect Pending Acquisition Of Loxo Oncology
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Eli Lilly And Co ::LILLY REPORTS STRONG FOURTH-QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS, LOWERS 2019 EPS GUIDANCE TO REFLECT THE PENDING ACQUISITION OF LOXO ONCOLOGY.SEES FY 2019 EARNINGS PER SHARE $4.57 TO $4.67.SEES FY 2019 NON-GAAP EARNINGS PER SHARE $5.55 TO $5.65.PLANS TO LAUNCH AN EXCHANGE OFFER TO LILLY SHAREHOLDERS IN FIRST HALF OF 2019 IN ORDER TO DIVEST ITS REMAINING OWNERSHIP INTEREST IN ELANCO ANIMAL HEALTH.FOURTH-QUARTER 2018 EARNINGS PER SHARE (EPS) GREW TO $1.10 ON A REPORTED BASIS.QTRLY ADJUSTED EARNINGS PER SHARE $$1.33.FOURTH-QUARTER 2018 WORLDWIDE TRULICITY REVENUE WAS $924.7 MILLION, AN INCREASE OF 42 PERCENT COMPARED WITH Q4 OF 2017.2019 EPS GUIDANCE RANGE LOWERED TO $4.57 TO $4.67 ON A REPORTED BASIS.FOR Q4 OF 2018, WORLDWIDE HUMALOG REVENUE DECREASED 2 PERCENT COMPARED WITH Q4 OF 2017, TO $770.4 MILLION.FOR Q4 OF 2018, WORLDWIDE TALTZ REVENUE WAS $307.0 MILLION, AN INCREASE OF 78 PERCENT COMPARED WITH Q4 OF 2017.QTRLY REVENUE $6,438.6 MILLION VERSUS $6,160.7 MILLION.2019 EPS GUIDANCE RANGE LOWERED TO AND $5.55 TO $5.65 ON A NON-GAAP BASIS.Q4 EARNINGS PER SHARE VIEW $1.34, REVENUE VIEW $6.29 BILLION -- REFINITIV IBES DATA.QTRLY REVENUE INCREASED 5 PERCENT, DRIVEN BY INCREASED DEMAND FOR NEWER MEDICINES, WHILE OPERATING EXPENSES INCREASED 1 PERCENT.ELI LILLY - 2019 EPS OUTLOOK CUT DUE TO ANTICIPATED IMPACTS OF PENDING ACQUISITION OF LOXO ONCOLOGY, NEGATIVE PHASE 3 CONFIRMATORY TRIAL FOR LARTRUVO.  Full Article

Elanco Animal Health Sees FY 2019 Adjusted EPS of $1.14 To $1.16
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Elanco Animal Health Inc ::ELANCO ANNOUNCES 2019 FINANCIAL GUIDANCE.SEES FY 2018 EARNINGS PER SHARE $0.15 TO $0.17.SEES FY 2019 REVENUE $3.1 BILLION TO $3.16 BILLION.SEES FY 2019 EARNINGS PER SHARE $0.36 TO $0.48.SEES FY 2018 REVENUE $3.05 BILLION TO $3.08 BILLION.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $1.14 TO $1.16.ELANCO ANNOUNCES 2019 FINANCIAL GUIDANCE.2019 REVENUE IS EXPECTED TO BE BETWEEN $3.10 BILLION AND $3.16 BILLION..2019 CORE REVENUE, WHICH EXCLUDES STRATEGIC EXITS IS EXPECTED TO BE $3.04 BILLION TO $3.10 BILLION.REAFFIRMS ITS EXPECTATION FOR 2018 EPS TO BE IN RANGE OF $1.14 TO $1.16..2019 REVENUE FROM STRATEGIC EXITS IS EXPECTED TO BE APPROXIMATELY $0.06 BILLION.FY2018 EARNINGS PER SHARE VIEW $1.21 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $3.12 BILLION -- REFINITIV IBES DATA.SEES 2019 ADJUSTED EPS OF $1.02 TO $1.12.FY2019 EARNINGS PER SHARE VIEW $1.08 -- REFINITIV IBES DATA.ELANCO - EPS IN 2018 ARE BEING ADJUSTED ON REPORTED BASIS DUE TO RESTRUCTURING ACTIONS AS PART OF CO'S PRODUCTIVITY AGENDA AND CHARGE.ELANCO ANIMAL - UNDERTAKING STEPS TO OPERATE AS A STAND-ALONE ENTITY, INCLUDING CREATING NECESSARY BACK-OFFICE AND GOVERNANCE STRUCTURES.  Full Article

FDA Approves Elanco's Experior
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES EXPERIOR FIRST ANIMAL DRUG THAT REDUCES GAS EMISSIONS FROM AN ANIMAL OR ITS WASTE.U.S. FDA SAYS GRANTED APPROVAL OF EXPERIOR TO ELANCO.  Full Article

Elanco Animal Health Q3 Adjusted Earnings Per Share $0.29
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Elanco Animal Health Inc ::ELANCO ANIMAL HEALTH REPORTS STRONG THIRD QUARTER RESULTS, PROVIDES FINANCIAL GUIDANCE FOR FULL YEAR 2018.Q3 ADJUSTED EARNINGS PER SHARE $0.29.Q3 EARNINGS PER SHARE $0.16.Q3 REVENUE $761.1 MILLION VERSUS I/B/E/S VIEW $765.5 MILLION.Q3 EARNINGS PER SHARE VIEW $0.25 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 EARNINGS PER SHARE $0.31 TO $0.33.SEES FY 2018 REVENUE $3.05 BILLION TO $3.08 BILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $1.14 TO $1.16.REMOVING IMPACT OF FOREIGN CURRENCY EXCHANGE RATES, QTRLY REVENUE GROWTH WAS 15 PERCENT.HAS DECIDED TO WITHDRAW APPLICATION FOR MARKETING AUTHORIZATION OF IMVIXA IN NORWAY.FY GUIDANCE REFLECTS IMPACT OF IMVIXA DISTRIBUTION WITHDRAWAL IN NORWAY.QTRLY REVENUE FROM STRATEGIC EXITS DECREASED 42 PERCENT FOR QUARTER.ELANCO ANIMAL HEALTH - SAW IMPACT OF $47.2 MILLION IN QUARTER FOR RESTRUCTURING & INTEGRATION COSTS, AMONG OTHERS.  Full Article

Deals of the day-Mergers and acquisitions

July 9 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday: